Introduction
============

Primary systemic vasculitis is characterised by inflammation and necrosis of blood vessel walls. The disease is broadly classified according to the size of the vessels involved, as proposed by the Chapel Hill Consensus Conference \[[@B1]\]. Further categorisation relies on clinical and histological findings, as well as the detection of autoantibodies. Three of the small vessel vasculitides - Wegener\'s Granulomatosis (WG), microscopic polyangiitis (MPA) and Churg-Strauss syndrome (CSS) - are typified by vasculitic lesions with little or no immune complex deposition and by anti-neutrophil cytoplasmic antibodies (ANCA). These diseases are collectively known as ANCA-associated systemic vasculitis (AAV).

Many clinical features are common to all types of AAV, including nonspecific inflammatory symptoms such as malaise, fever, anaemia and weight loss. Multiple organ systems may be affected; for example, vasculitic lesions may manifest as a rash, arthralgia, pulmonary haemorrhage and necrotising glomerulonephritis. There are, however, phenotypic differences between types of AAV:WG characteristically has ear, nose and throat and/or respiratory involvement. Necrotising granulomas may cause sinusitis, nasal discharge, damage to the nasal septum, hearing loss and/or haemoptysis. CSS is associated with asthma and eosinophilia. MPA commonly affects the kidney without evidence of granulomas, upper respiratory tract involvement or asthma.

The association with ANCA also varies: 80 to 90% of individuals with WG and MPA are ANCA-positive, compared with 40% of patients with CSS. The sensitivity for ANCA in the diagnosis of WG and MPA is 81 to 85%, whilst the specificity (if assayed by both immunoflourescence and ELISA) is 98% \[[@B2]\]. The type of ANCA varies with AAV subtype; MPA is predominantly associated with perinuclear ANCA (p-ANCA) antibodies to the enzyme myeloperoxidase (MPO), whilst patients with WG are more likely to have cytoplasmic ANCA (c-ANCA) antibodies to proteinase 3 (PR3) \[[@B3]\]. Nonetheless, there is considerable overlap between the classification of WG and MPA \[[@B3],[@B4]\].

AAV has a substantial morbidity and mortality; 15% of patients are dead within 1 year of diagnosis, and 35% are dead within 5 years \[[@B4]\]. Although 1-year survival rates are similar for all types of AAV (82.7 to 85.5%), survival at 5 years is worse in patients with MPA (45.1%) compared with WG and CSS (75.9% and 68.1%, respectively) \[[@B4]\].

The cause of AAV is not clear, although both environmental factors and genetic susceptibility have been implicated. A number of genetic polymorphisms have been associated with AAV, and with WG in particular. This suggests that the genetic contribution to AAV is polygenic, as with other autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE) and type 1 diabetes. In these diseases, genetic susceptibility is determined by relatively common variants that are found throughout the population, each of which contributes only modestly to disease risk. This has been termed the common disease, common variant hypothesis \[[@B5]\].

Epidemiology
------------

The incidence of AAV across different populations is broadly similar at 12 to 18 per million of population per year. The type of vasculitis varies, however, with WG being more common in populations from Norway and the UK, and MPA more common in Spain and Japan \[[@B6],[@B7]\]. The prevalence of WG in a predominantly Northern European Caucasian population from New Zealand was similar to that in the UK and Norway \[[@B8]\]. These population differences in the predominant type of AAV may reflect genetic differences and/or environmental factors.

Ethnic differences may influence both the type and incidence of AAV. Assessment of disease by ethnic distributions in US cohorts suggested WG is more prevalent in Caucasians than in African Americans \[[@B9]\]. In New Zealand in 2003, the 5-year incidence of WG was twice as high in individuals of European ancestry as in those of New Zealand Maori or Asian background, whereas Pacific Islanders had a rate approximately one-half that of New Zealand Maori or Asian \[[@B8]\]. Ethnicity may also be a risk factor for all types of AAV when environmental factors are controlled - in a French multi-ethnic population, AAV was twice as common in individuals of European, compared with non-European, ancestry \[[@B10]\], suggesting different degrees of genetic risk.

Genetics
========

More direct evidence for a genetic basis for WG comes from a recent familial aggregation study. This found a relative risk of 1.56 for first-degree relatives of patients with WG \[[@B11]\], which is similar to that seen in rheumatoid arthritis \[[@B12],[@B13]\] and suggests there are genetic risk factors for WG. In addition, case reports of familial clustering in AAV have reported polyarteritis nodosa and CSS occurring amongst relatives of patients with WG \[[@B14],[@B15]\], suggesting common genetic risk factors may predispose to different types of vasculitis.

A number of candidate gene association studies have identified variants associated with an increased incidence of AAV. Most of the genes so far described encode proteins involved in the immune response (Table [1](#T1){ref-type="table"}).

###### 

Positive genetic association studies in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis

  Gene                               Population origin          Cases                                  Controls        Odds ratio   *P*value        Reference
  ---------------------------------- -------------------------- -------------------------------------- --------------- ------------ --------------- ------------
  *HLA DPB1\*0401*                   Germany                    150 WG                                 100             3.9          1.5 × 10^-10^   \[[@B21]\]
  *HLA DPB1\*0401*                   Germany                    282 WG                                 380                          6.4 × 10^-8^    \[[@B22]\]
  *HLA B50*                          North America, Caucasian   83 WG                                  4,039           4.89^a^      \<0.0001        \[[@B18]\]
  *HLA DR9*                          North America, Caucasian   76 WG                                  4,039           4.00^a^      0.005           \[[@B18]\]
  *HLA DQw7*                         UK                         34 WG, 25 MPA                          1,103           2.9          \<0.0025        \[[@B19]\]
  *HLA DR3*                          UK                         34 WG, 25 MPA                          1,103           0.31         \<0.01          \[[@B19]\]
  *HLA DR1*                          UK                         27 WG                                  500 to 2,000?   2.3          0.0001          \[[@B20]\]
  *HLA DR4*                          The Netherlands            304 (241 WG, 30 MPA, 12 CSS, 21 RLV)   9,872           1.7          \<0.0001        \[[@B23]\]
  *HLA DR6*                          The Netherlands            304 (241 WG, 30 MPA, 12 CSS, 21 RLV)   9,872           0.3          \<0.0001        \[[@B23]\]
  *HLA DRB4*                         Italy                      48 CSS                                 350             2.49         2.3 × 10^-4^    \[[@B25]\]
  *HLA DRB3*                         Italy                      48 CSS                                 350             0.54         0.028           \[[@B25]\]
  *HLA DRB4*                         Germany                    102 CSS                                341             1.87         2 × 10^-4^      \[[@B24]\]
  *HLA DRB3*                         Germany                    102 CSS                                341             0.61         0.004           \[[@B24]\]
  *PTPN22-620W*                      Germany                    199 WG                                 399             1.8          0.002           \[[@B41]\]
  *PTPN22-620W*                      UK                         641 (WG, MPA and CSS)                  9,115           1.4          1.4 × 10^-4^    \[[@B43]\]
  *IL-2RA*rs41295061                 UK                         675 (WG, MPA and CSS)                  8,936           0.77         0.012           \[[@B42]\]
  *CTLA4*-318T                       Sweden                     32 WG                                  122             3.26         \<0.05          \[[@B46]\]
  *CTLA4*+49G                        The Netherlands            50 WG, 24 MPA, 7 CSS, 21 RLV           188             1.32         0.01            \[[@B48]\]
  *CTLA4*rs3087243                   UK                         641 (WG, MPA and CSS)                  9,115           1.19         6.4 × 10^-3^    \[[@B43]\]
  *PRTN3*-564G                       Germany                    66 WG                                  106             0.5          \<0.01          \[[@B30]\]
  *AAT Z*allele                      Italy                      33 WG, 28 MPA, 23 RLV                  200             3.7^a^       0.022           \[[@B36]\]
  *AAT Z*allele                      Austria                    29 WG, 2 MPA, 1 RLV                    868             13.2         \<0.0001        \[[@B37]\]
  *AAT Z*allele                      Germany                    79 WG                                  752             3.8^a^       \<0.0001        \[[@B35]\]
  *AAT Z*allele                      Sweden                     88 (66 WG)                             ?               6.0          \<0.0001        \[[@B95]\]
  *AAT Z*allele                      Scandinavia                44 WG                                  ?               ?            \<0.001         \[[@B34]\]
  *C3F*                              Sweden                     34 WG, 33 MPA                          101             0.52         \<0.05          \[[@B58]\]
  *CD18*Ava II                       Germany                    31 MPO positive                        120             2.56         \<0.005         \[[@B57]\]
  *IL-10*microsatellite              Sweden                     32 WG                                  109             7.94         \<0.0032        \[[@B51]\]
  *IL-10*(-1082) AA genotype         Germany                    125 WG, 36 MPA                         153             0.30         \<0.0001        \[[@B52]\]
  *IL-10*haplotype                   Germany                    103 CSS                                507             2.16         0.0003          \[[@B53]\]
  *LILRA2*intron 6                   Japan                      50 MPA                                 284             2.52         0.049           \[[@B54]\]
  AA genotype                                                                                                                                       
  *CD226*rs763361                    Germany                    642 WG                                 1226            1.20         0.016           \[[@B56]\]
  *FCGR2A*R131                       The Netherlands            91 WG                                  154             4.60         0.0092          \[[@B64]\]
  RR genotype with *FCGR3A*F158 FF                                                                                                                  
  *FCGR3B*copy number high           UK                         556 (WG, MPA and CSS)                  286                          1 × 10^-8^      \[[@B74]\]
  *FCGR3B*copy number low            UK                         80 WG                                  190                          0.003           \[[@B73]\]
  *FCGR3B*copy number low            UK                         76 MPA                                 190                          0.0003          \[[@B73]\]
  *FCGR3B*copy number low            France                     84 WG                                  181                          0.0001          \[[@B73]\]

CSS, Churg-Strauss syndrome; MPA, microscopic polyangiitis; MPO, myeloperoxidase; RLV = renal-limited vasculitis; WG, Wegener\'s granulomatosis. ^a^No odds ratio given in the reference; values calculated using Graphpad prism, 2 × 2 chi-squared test.

Replicated genetic associations
-------------------------------

### Major histocompatibility complex

The human MHC region spans 3.6 Mb containing more than 250 genes, more than one-half of which have immunological functions. Variants in MHC have been strongly associated with several autoimmune diseases, including type 1 diabetes \[[@B16]\] and SLE \[[@B17]\]. A number of small studies have suggested associations between WG and MHC loci, including *HLA-B50*\[[@B18]\], *HLA-DQw7*\[[@B19]\], *HLA-DR3*\[[@B19]\], *HLA-DR1*\[[@B20]\] and *HLA-DR9*\[[@B18]\].

More significantly, a recent study revealed a strong association of WG with an allele encoding class II molecule *DPB1\*0401*(odds ratio (OR) = 3.91, *P*= 1.51 × 10^-10^). In addition, the extended haplotype *DPB1\*0401/RXRB03*showed an even stronger association with WG (OR = 6.41, *P*= 7.13 × 10^-17^) \[[@B21]\], raising the possibility of additional susceptibility loci. A more recent study has replicated the association of the *DPB1\*0401*allele with WG. A single nucleotide polymorphism (SNP) 3\' of *HLA-DPB1*was most associated (*P*= 6.4 × 10^-8^), whilst another SNP in the vicinity of *RING1*(which encodes a transcriptional repressor) also showed a significant WG association that was partly independent of the *HLA-DPB1*effect \[[@B22]\]. The *HLA-DR4*allele was also associated with susceptibility to both AAV (in general) and WG (in a subset) in a study of 304 Dutch patients and 9,872 controls \[[@B23]\]. Between the four disease subsets (WG, MPA, CSS and renal-limited vasculitis), the HLA antigen distribution did not differ - except for DR8, which was more prevalent in patients with CSS than in the other three groups of AAV (*P*\< 0.0001) \[[@B23]\].

Two studies have identified an association between susceptibility to CSS and *HLA-DRB4*, whilst *HLA-DRB3*was associated with protection against the disease \[[@B24],[@B25]\]. As WG and CSS are thus associated with different HLA genotypes, it has been argued that they may in fact be separate disease entities, and not closely related disease variants as previously thought \[[@B24]\].

### PRTN3 gene

The genes encoding ANCA target antigens may play a role in the pathogenesis of AAV. *PRTN3*encodes PR3, an intracellular serum protease against which ANCA are commonly directed in WG. PR3 is also expressed on the surface expression of neutrophils. The expression pattern is bimodal in individuals; the proportion of neutrophils that are high or low expressers remains constant over time, and is unaffected by age or gender \[[@B26]\]. This surface expression pattern correlates much more closely in monozygotic twins (*r*= 0.99) than dizygotic twins (*r*= 0.06), suggesting it is genetically determined \[[@B27]\]. One study found that the distribution of membrane-bound PR3 in 37 AAV patients (16 with WG, 21 with MPA) was significantly skewed toward the membrane-bound PR3 high phenotype when compared with 126 healthy controls; 85% of AAV patients expressed high levels of membrane-bound PR3 versus 55% in healthy subjects \[[@B26]\]. This finding was replicated in a second study, which also showed that in 89 WG patients an elevated level of membrane-bound PR3 expression was significantly associated with an increased relapse rate (*P*= 0.011), but not with the disease extent or particular manifestations at diagnosis \[[@B28]\]. Interestingly, a study in 17 sibling pairs matched at 34 HLA antigens showed a high concordance in neutrophil membrane-bound PR3 expression (*r*= 0.67, *P*\< 0.05), approaching that seen in monozygotic twins \[[@B29]\]. The authors propose that the percentage of membrane PR3-positive neutrophils is dictated by HLA antigens, but do not suggest a mechanism for this effect.

Eight SNPs have been identified in the promoter and exonic sequences of *PRTN3*, and a polymorphism in the promoter region of *PRTN3*(A-564G), affecting a putative transcription factor binding site, was associated with WG when allele frequencies were compared in 66 cases and 106 controls \[[@B30]\]. This study also identified a strong association between a haplotype of two of these eight SNPs and WG (*P*\< 10^-5^). It has not yet been shown whether these polymorphisms affect PR3 expression.

Expression of membrane PR3 on neutrophils is therefore likely to be genetically determined, and individuals with high levels of expression are at increased risk of AAV. The genetic polymorphisms that cause this variation in expression have not been fully elucidated.

### α~1~-Antitrypsin

PR3 is released when activated neutrophils degranulate, and directly damages endothelial cells - *in vitro*, the enzyme causes detachment and cytolysis of endothelial cells. The cationic enzyme also binds covalently to the endothelium, where it can bind ANCA and thus trigger antibody-dependent cytotoxicity \[[@B31]\]. α~1~-Antitrypsin is the major inhibitor of PR3 activity, and is thought to limit the damage done to local tissues. The gene encoding α~1~-antitrypsin (*AAT*) is highly polymorphic, and several of the polymorphisms, including the Z and S alleles, reduce the function of the protein. The decreased function of α~1~-antitrypsin may result in persistence of PR3 in inflammatory tissue for longer, which may in turn result in the generation of ANCA.

Several groups have found an association of the presence of Z and S alleles with cANCA-positive and pANCA-positive vasculitis, respectively \[[@B32]\], anti-PR3 antibodies \[[@B33]\], WG \[[@B34],[@B35]\] or all AAV \[[@B36],[@B37]\]. Neither anti-PR3 antibodies nor clinical features of WG were detected in 191 α~1~-antitrypsin Z homozygotes \[[@B38]\], indicating that the deficiency contributes to, but is not the sole genetic determinant of, risk of AAV.

PTPN22 *gene*
-------------

*PTPN22*encodes protein tyrosine phosphatase non-receptor type 22, an enzyme expressed predominantly by lymphocytes. The 620W (rs2476601) allelic variant of *PTPN22*is associated with several autoimmune disorders, including type 1 diabetes mellitus, SLE and rheumatoid arthritis \[[@B39]\]. The associated allele appears to influence thresholds for T-cell receptor signalling, but the precise mechanisms for these associations remain unclear. In general, the *PTPN22*620W allele has been implicated in autoimmune disorders that have a prominent humoral component, suggesting that PTPN22 activity in B cells may be important \[[@B40]\].

A study of 199 WG patients found an increase in the *PTPN22*620W allele with an OR of 1.75 (95% confidence interval (CI) = 1.21 to 2.48, *P*= 0.002) \[[@B41]\]. We genotyped this SNP in 641 AAV cases derived from four UK sources, including 205 patients with WG and 74 patients with MPA (further details of these sample collections are given in \[[@B42]\]). We found an association of all AAV with the minor allele (*P*= 1 × 10^-4^, OR = 1.4; 95% CI 1.18 to 1.67), as well as an association with both WG and MPA when a subset of these patients with these diagnoses were analysed independently (WG, *P*= 6.0 × 10^-11^, OR = 2.0; MPA, *P*= 4.1 × 10^-6^, OR = 2.55) \[[@B43]\]. Thus, this SNP is likely to contribute to the risk of AAV, as well as other autoantibody-associated autoimmune diseases.

### Cytotoxic T-lymphocyte antigen 4

CTLA4 (cytotoxic T-lymphocyte antigen 4) is mainly expressed on CD4^+^T cells. When bound to its ligands (CD80 and CD86 on B cells and dendritic cells), CTLA4 inhibits T-cell function. Increased expression of CTLA4 is seen in WG \[[@B44]\]. Polymorphisms in *CTLA4*have been associated with a number of autoimmune diseases \[[@B45]\]. Heterozygosity for a SNP in the promoter region of *CTLA4*has been linked to WG \[[@B46]\], and this SNP has been shown to affect protein expression \[[@B47]\]. A small study of *CTLA4*SNPs did not find a significant association with this promoter polymorphism in a study of 102 patients and 188 controls, but found that a different SNP (+49G) was associated with AAV when individuals either heterozygote or homozygote for the G allele were compared \[[@B48]\]. We found an association of another autoimmune disease-associated SNP in *CTLA4*(rs3087243) with AAV in the 641 cases and 9,115 controls described above (*P*= 6.4 × 10^-3^, OR = 1.19; 95% CI = 1.05 to 1.34) \[[@B43]\]. The association of *CTLA*polymorphisms with other autoimmune diseases strengthens the case that SNPs in this gene to contribute to AAV susceptibility.

Unreplicated associations
-------------------------

### High-affinity IL-2 receptor

The cytokine IL-2 drives the division and survival of effector T cells, and is also important in regulatory T-cell homeostasis. Activated T cells and regulatory T cells express the high-affinity IL-2 receptor (IL-2RA or CD25). The receptor is also expressed on other immune cells including activated B cells, dendritic cells and activated monocytes, where its physiological role is less well defined. Polymorphisms in the *IL-2RA*locus have been associated with type 1 diabetes, multiple sclerosis and Graves\' disease \[[@B49]\]. When rs41295061, one of the SNPs associated with type 1 diabetes, was compared in 744 AAV cases (comprising WG, MPA and CSS) and 9,115 controls, the minor allele frequency was increased in AAV cases (*P*= 0.012, OR = 0.77; 95% CI = 0.63 to 0.95) \[[@B42]\]. Furthermore, soluble IL-2RA concentrations in the serum of AAV patients were higher than in controls, and disease activity as assessed by the Birmingham Vasculitis Activity Score also showed a positive correlation with soluble IL-2RA concentrations \[[@B42]\], as has previously been reported in WG patients \[[@B50]\]. The differences in soluble IL-2RA provide a physiological correlate of genetic variation that may contribute to the AAV risk.

### Interleukin-10

IL-10 is an anti-inflammatory cytokine produced primarily by monocytes and to a lesser extent by lymphocytes. This cytokine has pleiotropic effects on immunoregulation and inflammation. It downregulates the expression of Th1 cytokines, MHC class II antigens, and co-stimulatory molecules on macrophages. It also enhances B-cell survival, proliferation, and antibody production. A small study of 32 WG patients found an association with a polymorphism in *IL-10*that has previously been associated with autoantibody production \[[@B51]\]. A larger study of 125 WG cases and 153 controls also found a SNP in *IL-10*was associated with WG \[[@B52]\], with homozygosity for the minor allele over-represented in the patients (*P*= 0.0021; OR = 0.354; 95% CI = 0.183- 0.684). Conversely, a study of 403 WG patients did not find an association with three SNPs in *IL-10*, although a haplotype was associated with ANCA-negative CSS \[[@B53]\]. Further studies are needed to clarify the role of polymorphisms in the gene encoding this anti-inflammatory cytokine.

### Leukocyte immunoglobulin-like receptor A2

LILRA2 is one member of the family of leukocyte immunoglobulin-like receptors. The leukocyte immunoglobulin-like receptors in subfamily A initiate stimulatory cascades, and LILRA2 is involved in the activation of granulocytes and macrophages. A SNP in *LILRA2*(rs2241524 G\>A) activates a cryptic splice acceptor site, resulting in a novel LILRA2 isoform. Homozygosity for the minor allele of SNP was associated with both SLE and MPA in a recent study \[[@B54]\], although only 50 MPA patients were included.

*CD226*gene
-----------

CD226 (DNAX accessory molecule 1) is an immunoglobulin superfamily adhesion molecule expressed on the surface of natural killer cells, platelets, monocytes and T cells. It binds CD155, which is found on epithelial cells, endothelial cells and antigen-presenting cells. CD226 appears to contribute to multiple innate and adaptive responses, including leukocyte migration, activation and expansion differentiation of CD8 T cells and CD4 T cells, and effector responses of T cells and natural killer cells \[[@B55]\]. The minor allele of a polymorphism in CD226, rs763361, which encodes a glycine to serine substitution at position 307, was associated with disease in two German WG cohorts (OR = 1.23, *P*= 0.0031), but not in a UK cohort \[[@B56]\]. When we studied this polymorphism in 641 UK cases and 9,115 controls, we did not find an association with AAV, or with WG in a subset analysis \[[@B43]\]. This suggests that the disease risk associated with the minor allele of this polymorphism is much smaller in UK Caucasians than in German Caucasians.

### Associations with other single nucleotide polymorphisms

A SNP in the gene encoding integrin CD18, a leucocyte adhesion molecule, has been associated with MPO ANCA-positive AAV \[[@B57]\], and another in the gene for complement component C3 has been associated with a combination of WG and MPA \[[@B58]\]. These studies are too small to be conclusive without replication.

Several groups have looked for an association between AAV and polymorphisms in *TNF*genes (encoding the proinflammatory cytokines TNFα and TNFβ), and none have shown statistically significant differences \[[@B59],[@B60]\].

Fcγ receptors
-------------

The low-affinity Fcγ receptors (FcγRs) bind the Fc portion of IgG and mediate the effects of IgG immune complexes on leucocytes, resulting in immune responses that include recruitment to inflammatory lesions, phagocytosis, antibody-dependent cellular cytotoxicity, release of inflammatory mediators and antibody production. The activation of primed neutrophils by ANCA requires FcγRs. Human neutrophils constitutively express the low-affinity activatory FcγRs, FcγRIIa (CD32) and FcγRIIIb (CD16), and both of these receptors have been shown to play a role in ANCA-induced neutrophil activation \[[@B61]\]. ANCA crosslink MPO and PR3 with these FcγRs to trigger intracellular signalling, which results in superoxide production, proinflammatory cytokine release and degranulation \[[@B31]\]. Both *FCGR2A*and *FCGR3B*have functionally significant polymorphisms.

### Fcγ receptor IIa

FcγRIIa is a low-affinity, activatory FcγR expressed on monocytes, macrophages, platelets and activated dendritic cells as well as neutrophils. A polymorphism in *FCGR2A*results in a histidine to arginine substitution at amino acid position 131, altering receptor affinity and specificity for IgG subtypes - FcγRIIa-H/131 binds IgG~2~and IgG~3~with increased avidity compared with the FcγRIIa-R131 homozygous genotype. In acute AAV, IgG~3~predominates \[[@B62]\] and sera with higher IgG~3~ANCA levels can preferentially activate neutrophils \[[@B63]\]. The FcγRIIa-R131 homozygous genotype, in combination with homozygosity for an allelic form of FcγRIIIa, was over-represented in Dutch patients with WG, and was also associated with increased disease relapse rates \[[@B64]\]. Individuals with the FcγRIIa-R131 homozygous genotype have a reduced ability to phagocytose *Staphlococcus aureus*, which provokes an IgG~2~antibody response \[[@B65]\]. Chronic nasal carriage of *S. aureus*has been associated with higher relapse rates in patients with WG \[[@B66]\], and thus the FcγRIIa-R131 homozygous genotype may predispose to WG relapse by reducing clearance of the bacterium. In a British study, however, no significant association was found between FcγRIIa genotype and ANCA-positive vasculitis or nephritis in 107 patients and 100 controls \[[@B67]\], although this study was powered to detect a minimum OR of 2.48, and smaller effect sizes cannot be excluded.

### Fcγ receptor IIIb

FcγRIIIb is a low-affinity, glycosylphosphatidylinositol-linked FcγR expressed only on human neutrophils. The receptor is activatory, and is thought to signal through association with complement receptor 3, FcγRIIa, or lipid rafts. FcγRIIIb can also be released from the surface of neutrophils upon activation. *FCGR3B*has two polymorphic forms, which differ by five nucleotides (141, 147, 227, 277, and 349) within exon 3, resulting in a fouramino-acid substitution in its membrane-distal immunoglobulin-like extracellular domain. This gives rise to two isoforms termed FγRIIIb-HNA1a and FcγRIIIb-HNA1b (previously known as NA1 and NA2, respectively), which have different IgG subtype affinities. FcγRIIIb-HNA1a has a higher affinity for IgG~3~, so might be expected to be associated with AAV. ANCA responses are greater in neutrophils from FcγRIIIb-HNA1a donors \[[@B68]\], and one study has shown a nonsignificant trend to an association of *FCGR3B HNA1a*with AAV \[[@B68]\]. However, *FCGR3B*has recently been shown to be present at variable copy number (see below), and these association studies need to be reinterpreted in the light of analysis of CNV.

### Copy number variation

Copy number variation has been defined as a DNA segment that is 1 kb or larger and is present at variable copy numbers in comparison with a reference genome. As much as 5% of the human genome may lie within copy number variable regions \[[@B69]\]. The implications of such widespread genetic copy number variation on phenotypic variation are as yet uncertain, but some copy number variants clearly have a functional effect. For example, the copy number of *CCL3LI*has been associated with susceptibility to SLE \[[@B70]\], rheumatoid arthritis \[[@B71]\] and type 1 diabetes \[[@B71]\]. SLE has also been associated with variable copy number in the genes encoding complement component C4 \[[@B72]\], as well as in *FCGR3B*\[[@B73],[@B74]\]. *In vitro*studies have shown that the *FCGR3B*copy number correlates with protein expression, with neutrophil uptake of and adherence to immune complexes, and with soluble serum FcγRIIIb \[[@B74]\].

There is controversy regarding the association of *FCGR3B*copy number with AAV: Fanciulli and colleagues showed an association with low copy number in two WG cohorts of 80 and 84 patients, and in an MPA cohort of 76 patients \[[@B73]\]; whilst Willcocks and colleagues compared 556 patients with AAV from three different cohorts with 286 controls, and found in all three cohorts that AAV was associated with high *FCGR3B*copy number \[[@B74]\]. Copy number assays, however, often produce results that are continuously distributed across the population, rather than falling into discrete bins associated with copy numbers \[[@B75]\]. Difficulties in copy number assignation may therefore underlie these conflicting results. The association of the *FCGR3B*copy number with AAV needs to be reassessed now a more reliable copy number assay has been described \[[@B76]\].

Thus, although *in vitro*data implicate the FcγRs in mediating the actions of ANCA on neutrophil activation, a definitive view on the contribution of genetic variation in the *FCGR*locus to AAV requires a study which takes into account both SNPs, CNV and their potential interactions.

Summary of genetic evidence
---------------------------

Many genetic factors have been implicated in the pathogenesis of AAV. The increased risk in family members with WG is comparable with that seen in rheumatoid arthritis, for which genetic risk factors have been well characterised. Indeed, the genes with variants most strongly associated with AAV, the MHC and *PTPN22*genes, also have variants associated with other autoimmune diseases, including rheumatoid arthritis, type 1 diabetes and SLE \[[@B39],[@B45]\]. This suggests that genetic risk factors common to other autoimmune diseases also apply to AAV. Different variants within each gene may be associated with different polymorphisms - for example, SLE associates with IL-2RA SNP rs11594656, while AAV is associated with rs41295061 \[[@B42]\]. Table [1](#T1){ref-type="table"} summarises results from positive genetic association studies performed to date. Most of these studies are either composed solely of patients with WG, or include a majority of patients with this type of AAV. It is not yet clear whether this is because the genetic contribution to WG is greater than that seen in the other types of AAV or whether this simply reflects the case mix of AAV in Northern European countries, where most of these studies have been performed. Larger cohorts need to be studied to allow subset analysis of the different types of AAV.

Several common autoimmune diseases have been the subject of genome-wide association studies, in which hundreds of thousands of SNPs throughout the genome are compared in cases and controls. These studies have identified new associations with variants in genes not previously known to be involved in pathogenesis; for example, in inflammatory bowel disease, the genes involved in the autophagy pathway \[[@B77]\]. Such associations identify new approaches for diagnosis and treatment, and a genome-wide study of AAV may be similarly enlightening.

Environmental triggers and anti-neutrophil cytoplasmic antibody-associated systemic vasculitis
==============================================================================================

The environmental agents that trigger the onset of AAV in genetically susceptible individuals remain elusive in the majority of patients. Epidemiological evidence suggests that the AAV is more common in people chronically exposed to a wide variety of environmental toxins, including pesticide, livestock, high solvent exposure, asbestos, hydrocarbon fumes and silica (reviewed in \[[@B78]\]). Evidence for causality is strongest for silica: exposed patients typically have the clinical syndrome of MPA and have ANCA that include specificity for MPO rather than for PR3 \[[@B79]\]. The mechanisms are unknown but could relate to the chronic proinflammatory effects of silica on macrophages and the consequent adjuvant effect of adaptive immune responses \[[@B80]\].

Drugs
-----

The evidence that therapeutic drugs can induce AAV is more convincing. As many as one-half of patients treated with the anti-thyroid drug propylthiouracil may develop positive ANCA and anti-MPO assays, although far fewer develop overt vasculitis \[[@B81]\]. AAV has been reported after treatment with hydralazine for hypertension \[[@B82]\] and after penicillamine therapy for rheumatic disease \[[@B83]\], in both cases with pANCA-associated focal necrotising glomerulonephritis.

Infections
----------

As only a small fraction of those presenting with AAV are exposed to these chemical triggers, other environmental agents must be involved, and these are commonly assumed to be infections, a view re-enforced by increasing evidence that bacterial infections are the initial event that breaks tolerance, resulting in autoimmunity in other contexts. Attempts to use data on the seasonal incidence of AAV to support a role for infection have been unhelpful - some studies have suggested that the incidence of WG is higher in the winter, when infection rates are higher, but other studies have not confirmed this suggestion (reviewed in \[[@B78]\]). Nonetheless, nearly two-thirds of patients presenting with WG are nasal carriers of *S. aureus*(significantly higher incidence than the general population) and nasal colonisation with *S. aureus*greatly increases the risk of disease relapse (relative risk 7.2), suggesting direct involvement \[[@B66]\]. Furthermore, in a randomised controlled trial, prophylactic treatment with co-trimoxazole reduced relapse rates by 60% \[[@B84]\]. ANCA positivity has been reported in patients with bacterial endocarditis, some of whom develop features of vasculitis \[[@B85]\]. In two of these, *S. aureus*was the causative organism \[[@B86],[@B87]\], which may again point to a link between this species and AAV.

Molecular mimicry between pathogen and host proteins is often proposed as an explanation for the association between infection and autoimmunity \[[@B88]\]. This occurs when exposure to foreign proteins provokes synthesis of antibodies that cross-react with host proteins due to sequence or structural similarities. The resulting autoantibodies then cause disease. In an era of database searches, however, it is remarkably simple to find sequence homologies over eight to 10 amino acids that might be contained in a B-cell epitope. Consequently, claims for molecular mimicry need to be judged against stringent criteria before they can be accepted \[[@B89]\].

The evidence for *S. aureus*being a molecular mimic does not meet these standards: there are no known homologies between *S. aureus*proteins and the common ANCA targets MPO, PR3 and the more recently described LAMP-2 \[[@B90]\]; and similarly there are no suggestions that ANCA bind directly to *S. aureus*. No homologies have been identified between *S. aureus*proteins and the common ANCA targets, and no evidence has been published suggesting that ANCA themselves bind to *S. aureus*proteins. Accordingly there is no evidence that *S. aureus*is a conventional molecular mimic.

Pendergraft and colleagues suggested a more complex form of molecular mimicry to link *S. aureus*with anti-PR3 antibodies \[[@B91]\]. They noted that a proportion of patients with AAV and anti-PR3 antibodies also had circulating antibodies that recognised the complementary PR3 sequence - i.e. the protein that would result from transcription of the antisense strand of the PR3 gene. When they immunized mice with complementary PR3, antibodies developed to both complementary PR3 and subsequently to PR3, thus in mice at least, anti-PR3 and anti-complementary PR3 antibodies are idiotypes for each other \[[@B91]\]. Intriguingly, there is a weak homology between complementary PR3 and *S. aureus*proteins, and Pendergraft *et al*. suggested exposure to *S. aureus*induced anti-complementary PR3 antibodies that in turn induced anti-PR3 antibodies and AAV. However, there is no evidence that anti-complementary PR3 antibodies cross-react with *S. aureus*. Furthermore, rodents immunised with *S. aureus*do not develop AAV \[[@B92]\] - although, interestingly, immunisation with *Escherichia coli*used as a control in this study did induce AAV in a small proportion of animals.

Until recently, attempts to link bacterial infection and AAV have been based on the idea that autoantibodies to the classical ANCA targets MPO and PR3 are the cause of AAV, but this is still the subject of considerable debate. These antibodies are closely associated with AAV and its activity, and there is compelling evidence that they can cause endothelial injury *in vitro*, and *in vivo*in the case of anti-MPO antibodies (reviewed in \[[@B31]\]). Kain and colleagues recently provided evidence that antibodies to LAMP-2 may have a pathogenic role in AAV, as well as providing evidence of molecular mimicry between LAMP-2 and the bacterial adhesion protein FimH \[[@B90]\].

LAMP-2 is a heavily glycosylated type 2 membrane protein found in high concentrations in lysosomes that also shuttles to the cell surface. Surface LAMP-2 has a role in cell adhesion, whilst intracellular LAMP-2 is critical for autophagy and presentation of intracellular antigens \[[@B93]\]. In neutrophils, LAMP-2 is found in the same vesicles as MPO and PR3 - consequently, autoantibodies to LAMP-2 give positive results in fluorescent ANCA assays. LAMP-2 is also present on the cell membrane, however, and is immediately accessible to circulating auto anti bodies \[[@B94]\].

Kain and colleagues found that autoantibodies to LAMP-2 were present in over 90% of a cohort of 84 patients with active AAV and pauci-immune focal necrotising glomerulonephritis, whereas autoantibodies to MPO and PR3 were each found in just under one-half of patients \[[@B90]\]. By contrast, assays to anti-LAMP-2 antibodies were negative when patients were in remission. A monoclonal antibody to human LAMP-2 activated neutrophils *in vitro*and induced apoptosis of human endothelial cells. Rats injected with polyclonal anti-LAMP-2 antibodies developed severe pauci-immune focal necrotising glomerulonephritis, confirming that the antibodies could be pathogenic.

Epitope mapping identified two dominant epitopes recognised by patients\' autoantibodies, one of which, termed P~31.39~, was homologous (with eight out of nine amino acids identical) to a sequence in the mannose binding pocket of FimH, an adhesin expressed by Gramnegative bacteria. Patients\' autoantibodies cross-reacted with FimH, and rats immunised with FimH developed anti-FimH antibodies that cross-reacted with human and rat LAMP-2. The immunised rats also developed AAV with pauci-immune focal necrotising glomerulonephritis. Kain and colleagues hypothesise that molecular mimicry between the two proteins causes antibodies to LAMP-2 in susceptible individuals after infection with fimbriated bacteria, and this in turn causes AAV (as illustrated in Figure [1](#F1){ref-type="fig"}). More data will be needed to confirm this novel hypothesis.

![**Proposed mechanism of action for antibodies to LAMP-2 in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis**\[[@B90]\]. **(a)**Antibodies develop to FimH, an antigen found on fimbriated bacteria such as *E. coli*, develop during an infection. **(b)**In genetically susceptible individuals, these antibodies cross react with LAMP2, a widely-expressed protein found on cell surfaces as well as in lysosomes. **(c)**The auto-antibodies bind to LAMP2 on the surface of neutrophils and endothelial cells causing apoptosis. **(d)**Antibodies to LAMP2 may also mediate adherence of neutrophils to endothelial cells via Fcγ receptors. **(e)**Subsequent neutrophil degranulation causes endothelial cell necrosis and thus vasculitis.](ar2928-1){#F1}

Conclusion
==========

In summary, we have reviewed evidence that strongly supports the existence of genetic risk factors for AAV. As with other polygenic autoimmune diseases - for example, rheumatoid arthritis and SLE - AAV is likely to result from complex interactions between genetic variants and environmental triggers. Infection may trigger AAV, and we have outlined a number of possible mechanisms for this trigger. In particular, we have discussed a recently reported example of molecular mimicry which provides a new model for the pathogenesis of this autoimmune disease \[[@B90]\].
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